These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 27564469

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice.
    Fernández-Ruiz M, Arias M, Campistol JM, Navarro D, Gómez-Huertas E, Gómez-Márquez G, Díaz JM, Hernández D, Bernal-Blanco G, Cofan F, Jimeno L, Franco-Esteve A, González E, Moreso FJ, Gómez-Alamillo C, Mendiluce A, Luna-Huerta E, Aguado JM, OPERA Study Group.
    Transpl Int; 2015 Sep; 28(9):1042-54. PubMed ID: 25864986
    [Abstract] [Full Text] [Related]

  • 4. Decreased Cytomegalovirus infection after antilymphocyte therapy in sirolimus-treated renal transplant patients.
    Ozaki KS, Câmara NO, Galante NZ, Camargo LF, Pacheco-Silva A.
    Int Immunopharmacol; 2005 Jan; 5(1):103-6. PubMed ID: 15589467
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients.
    Lim WH, Eris J, Kanellis J, Pussell B, Wiid Z, Witcombe D, Russ GR.
    Am J Transplant; 2014 Sep; 14(9):2106-19. PubMed ID: 25088685
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Experience with belatacept rescue therapy in kidney transplant recipients.
    Brakemeier S, Kannenkeril D, Dürr M, Braun T, Bachmann F, Schmidt D, Wiesener M, Budde K.
    Transpl Int; 2016 Nov; 29(11):1184-1195. PubMed ID: 27514317
    [Abstract] [Full Text] [Related]

  • 13. The influence of mTOR inhibitors on the incidence of CMV infection in high-risk donor positive-recipient negative (D+/R-) kidney transplant recipients.
    Cristelli MP, Esmeraldo RM, Pinto CM, Sandes-Freitas TV, Felipe C, Lobo CF, Viana L, Mansur J, Stopa S, Santos DWC, Grenzi PC, Aguiar WF, Tedesco-Silva H, Pestana JOM.
    Transpl Infect Dis; 2018 Aug; 20(4):e12907. PubMed ID: 29679515
    [Abstract] [Full Text] [Related]

  • 14. Use of mTOR inhibitor as prophylaxis for cytomegalovirus disease after kidney transplantation: A natural experiment.
    Cristelli MP, Felipe CR, Prizmic PSS, de Azevedo VFD, Viana LA, Tavares MG, Wagner de Castro Lima Santos D, de Paula MI, Medina-Pestana JO, Tedesco-Silva Junior H.
    Clin Transplant; 2019 Oct; 33(10):e13689. PubMed ID: 31400155
    [Abstract] [Full Text] [Related]

  • 15. Impact of ganciclovir prophylaxis on cytomegalovirus infection in recipients of cadaveric renal allografts.
    Ram Peddi V, Hariharan S, Schroeder TJ, First MR.
    Nephron; 1997 Oct; 76(1):49-55. PubMed ID: 9171300
    [Abstract] [Full Text] [Related]

  • 16. Conversion From Calcineurin Inhibitors to Mammalian Target of Rapamycin Inhibitors in Kidney Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Zeng J, Zhong Q, Feng X, Li L, Feng S, Fan Y, Song T, Huang Z, Wang X, Lin T.
    Front Immunol; 2021 Oct; 12():663602. PubMed ID: 34539621
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Immunological Results of Long-Term Use of Mammalian Target of Rapamycin (mTOR) Inhibitors and Its Effects on Renal Graft Functions.
    Tanrısev M, Ayna Kılıçaslan T, Çolak H, Ersan S, Yılmaz B, Alp A, Tuğmen C, Sevgili BE.
    Ann Transplant; 2021 Sep 17; 26():e932434. PubMed ID: 34531361
    [Abstract] [Full Text] [Related]

  • 19. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group.
    Falagas ME, Snydman DR, Ruthazer R, Griffith J, Werner BG, Freeman R, Rohrer R.
    Clin Transplant; 1997 Oct 17; 11(5 Pt 1):432-7. PubMed ID: 9361936
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.